Spyre Therapeutics (SYRE) is trading higher as investors digest the pricing of the company’s upsized underwritten public offering. The deal was priced at $62.00 per share for 6,500,000 shares, implying expected gross proceeds of about $403.0 million before fees and expenses, with closing expected on or about April 16, 2026, subject to customary conditions. (globenewswire.com)

While follow-on offerings are typically dilutive, the market can read a sharply upsized raise as a sign of strong institutional demand and improved financing certainty. With SYRE trading above the offering price, buyers appear to be treating the discounted supply as absorbed, while focusing on the company’s strengthened cash runway and ability to fund broader clinical development.

The financing comes days after Spyre reported positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY001 in moderate-to-severely active ulcerative colitis. The company said SPY001 met its primary endpoint, posting a statistically significant reduction of 9.2 points from baseline at Week 12 in the Robart’s Histopathology Index (RHI), with secondary endpoints that included 40% clinical remission and 51% endoscopic improvement. (stocktitan.net)

Near-term trading will likely key off (1) how the stock trades around the $62.00 deal price as new shares are distributed, and (2) any exercise of the 30-day underwriter option for additional shares. On the clinical side, the next major focus is additional SKYLINE readouts the company has guided for later in 2026 for other cohorts/programs, as investors re-rate the platform around durability, dosing convenience, and competitive positioning in IBD. (globenewswire.com)